Introduction {#sec1-1}
============

Lung cancer is the leading cause of cancer-related death worldwide (Jemal A et al., 2011). Lung adenocarcinoma, the most common type of primary lung cancer, is diagnosed in 1 million patients each year (Siegel R et al., 2014). Targeted therapy has been successful in a subset of lung adenocarcinoma patients with driver oncogenic mutations (Lynch TJ et al., 2004). However, the effect is still insufficient, and lung adenocarcinoma is still associated with a high rate of mortality.

Studies have found that the prognosis of cancer is related to inflammation (Mei Z et al., 2014). Inflammation-based prognostic scores have been developed to predict the prognosis of cancer patients. The Glasgow Prognostic Score (GPS), which is based on serum albumin and C-reactive protein (CRP) levels, is the most commonly used scoring system (Al Murri AM et al., 2006). Recently, the GPS has been reported to be a prognostic factor for patients with cancer (Mimatsu K et al., 2014: La Torre M et al., 2012: Horino K et al., 2013: Vashist YK et al., 2011). An elevated GPS has been shown to be associated with a worse prognosis in patients with inoperable non-small cell lung cancer (NSCLC) (Forrest LM et al., 2003: Forrest LM et al., 2005). Furthermore, Tomita et al. reported that the preoperative GPS may be useful to predict the prognosis of patients with NSCLC (Tomita M et al., 2014); however, the report did not focus patients with lung adenocarcinoma, which is relatively homogeneous group. We therefore examined postoperative survival, according to the GPS, in patients with resected pulmonary adenocarcinoma.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

We retrospectively reviewed a database of 156.0 continuous patients (75.0 men and 81.0 women) who underwent lobectomy at Kanazawa Medical University between 2002 and 2012. All patients underwent pulmonary lobectomy and had histologically-confirmed primary pulmonary adenocarcinomas. Tumors were classified according to the TNM classification (7th edition) (Goldstraw P et al., 2007). The study was approved by the Institutional Review Board of Kanazawa Medical University, Ishikawa, Japan (I045).

Measurement of Glasgow prognostic score {#sec2-2}
---------------------------------------

The blood sample collection was performed on admission. The GPS definitions were as follows: Patients with a CRP level of \< 10 mg/L and an albumin level of \>35 g/L were allocated to GPS 0. If only the CRP was increased or the albumin level was decreased, the patients were allocated to GPS1. The patients in whom the CRP level was \>10 mg/L and the albumin level was \<35 g/L were classified as GPS 2. This study is a retrospective design.

Statistical analysis {#sec2-3}
--------------------

The prognostic factors were examined using both univariate and multivariate analyses. The disease-free survival (DFI) rates and overall survival (OS) rates were calculated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios and confidence intervals were estimated with the use of a stratified Cox proportional-hazards model. P values of \<0.05 were considered to indicate statistically significance. All statistical analyses were performed using the StatView software program (SAS Institute Inc, Cary, NC).

Results {#sec1-3}
=======

The baseline patient characteristics are shown in [Table 1](#T1){ref-type="table"}. The median age of the patients was 65.2 years (range: 31-83). The GPS of the study patients were as follows: GPS0 (n=136, 87.2%), GPS1 (n=16, 10.3%), and GPS2 (n=4.0, 2.5%). Seventy-five patients (48.1%) were male and Eighty-nine patients (57.1%) were smokers. The pathological stages of the patients were as follows: IA (n=78, 50%), IB (n=31, 19.9%), IIA (n=20, 12.8%), IIB (n=9, 5.7%), IIIA (n=18.0, 11.5%). Forty-nine (31.4%) patients had comorbidities. Relationships between GPS and clinicopathological features of the patients are shown in [Table 2](#T2){ref-type="table"}. Stage and tumor size show significant relationship with GPS.

###### 

The Patients' Characteristics

                               No. of Patients   \%
  ----------------- ---------- ----------------- ------
  Age               \>=65      86                55.1
                    \<65       70                44.9
  Gender            male       75                48.1
                    female     81                51.9
  Smoking           \+         89                57.1
                    \-         67                42.9
  Stage             IA         78                50.0
                    IB         31                19.9
                    IIA        20                12.8
                    IIB        9                 5.7
                    IIIA       18                11.5
  Tumor Size        \>=3.0cm   57                36.5
                    \<3.0cm    99                63.5
  LN metastasis     \+         33                21.2
                    \-         123               78.8
  Differentiation   1.2        142               91.0
                    3.4        14                9.0
  GPS               0.0        136               87.2
                    1.0        16                10.3
                    2.0        4                 2.5

###### 

Clinicopathological Characteristics of Study Participants

                              GPS0   GPS1/2   p value
  ----------------- --------- ------ -------- ---------
  Gender            male      62     13       0.167
                    female    74     7        
  Smoking           \+        81     8        0.159
                    \-        55     12       
  Age               \>=65     72     14       0.234
                    \<65      64     6        
  Stage             I         102    7        0.001
                    II/IIIA   34     13       
  Tumor size        \>=3cm    45     12       0.037
                    \< 3cm    91     8        
  LN metastasis     \+        25     8        0.055
                    \-        111    12       
  Differentiation   1.2       124    18       1.000
                    3.4       10     2        

The 5-year survival rates of patients with GPS 0, 1 and 2 were 86.7%, 56.3% and 25%, respectively ([Figure 1](#F1){ref-type="fig"}). The 5-year survival rates of GPS 1/2 was significant.

![The Cancer-Specific Survival of GPS0, 1 and 2 in Lung Adenocarcinoma Patients](APJCP-17-4677-g001){#F1}

The median follow-up period of the survivors was 48.0 months. During the follow-up period, 33 (21.2%) patients died. A Kaplan-Meyer method revealed a significant association between the GPS and the disease-free survival (p=0.001) ([Figure 2](#F2){ref-type="fig"}), and overall survival (p\<0.001) ([Figure 3](#F3){ref-type="fig"}). Gender (p=0.011), Smoking (p\<0.001), Tumor size (p=0.001), Lymph node metastasis (p\<0.001), Differentiation (G3/4) (p=0.047) and GPS (p\<0.001) were significantly associated with cancer-specific survival in a univariate analysis ([Table 3](#T3){ref-type="table"}). The multivariate analysis of these significant variables showed the GPS (HR: 2.9 95% CI: 1.25 -6.67 p=0.013), smoking and tumor size to be independently associated with cancer-specific survival ([Table 4](#T4){ref-type="table"}).
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###### 

A Univariate Survival Analysis Examining the Association between the Glasgow Prognostic Scores (GPS) and Survival

  Parameter                HR    95% CI     P value
  ------------------------ ----- ---------- ---------
  Age(\>=65)               1.5   0.7-3.1    0.249
  Gender                   0.4   0.2-0.8    0.011
  Smoking                  3.9   1.8-8.3    \<0.001
  Tumor Size(\>=3cm)       4.3   2.0-9.1    0.001
  LN Metastasis            4.6   2.3-9.3    \<0.001
  Differentiation (G3.4)   2.7   1.0-6.9    0.047
  GPS                      5.5   2.6-11.7   \<0.001

###### 

The Results of a Multivariate Survival Analysis Examining the Association between the Glasgow Prognostic Scores (GPS) and Survival

  Palameter                HR    95% CI    p value
  ------------------------ ----- --------- ---------
  Gender                   1.6   0.6-4.7   0.372
  Smoking                  3.1   1.1-9.1   0.04
  Tumor Size(\>=3cm)       2.9   1.3-6.7   0.011
  LN metastasis            2.0   0.9-4.5   0.904
  Differentiation (G3.4)   0.6   0.1-4.4   0.63
  GPS                      2.9   1.2-6.7   0.013

Discussion {#sec1-4}
==========

Many cancers arise from sites of infection, chronic irritation and inflammation (Coussens LM et al., 2002). The association between inflammation and lung cancer has been extensively reported (Tauler J et al., 2009). Recently, There are reports about the relationship between the GPS and resected lung cancer (Tomita M et al., 2014: Miyazaki T et al., 2015). However, there are no reports on relationship between GPS and resected lung adenocarcinoma. We therefore investigated the relationship between the GPS and resected lung adenocarcinoma.

The GPS was found to be correlated with the Stage and tumor size in the present study. Cancer progression releases inflammatory cytokines and growth factors. These are increased as part of the systemic inflammatory response (Canna K et al., 2008) and lead to the production of CRP. When the inflammatory reaction advances, the systemic nutritional status worsens, and the albumin value decreases. Thus, the GPS seemed to be related to the progression, which is reflected by the stage and tumor size. Because GPS may be involved to the LN factor, the LN factor was not associated in survival by multivariable analysis.

In the present study, we found that the GPS predicted the prognosis as well as the pathological stage of 156.0 patients who underwent lobectomy for adenocarcinoma. The GPS was associated significantly shorter disease-free survival rates and overall survival in resected lung adenocarcinoma. Moreover, a multivariate analysis revealed that the GPS was a significant prognostic factor for overall survival. Our findings suggest that, similar to other cancers, the GPS could be a very important factor for predicting the prognosis of patients with resected adenocarcinoma of the lung. However, the results should be interpreted with caution because the present study involved a short observation period and a small number of cases.

Recently, in NSCLS, it was reported that GPS were positive correlatived with cytokeratin 19 fragment antigen 21-1(CYFRA21-1), carcinoembryonic antigen (CEA) and tissue polypeptide specific antigen (TPS) in patients with advanced NSCLS (Jiang AG et al., 2015). GPS of score 2 predicts a prolonged ICU stay in patients undergoing pneumonectomy (Petrella F et al., 2016). Furthermore, in the other cancers, the presence of a systemic inflammatory response, as evidenced by the GPS, appears to be superior to the subjective assessment of a patient's performance status (PS) in predicting the response to platinum-based chemotherapy in patients with advanced gastroesophageal cancer (Crumley AB et al., 2008). The GPS was also found to be an independent negative prognostic factor for overall survival in esophageal cancer patients treated with the combination chemotherapy of docetaxel and nedaplatin as a second-line chemotherapy (Kawabata R et al., 2011). We therefore suggest that the GPS is useful index that is simple and easy to implement in the clinical setting, not only surgery cases but also in chemotherapy cases. These characteristics will make the GPS an important index for various fields.

This study has same limitations. This study is retrospective design. In future, prospective study will be necessary. In conclusion, the GPS was demonstrated to be correlated with poor survival. The GPS is therefore important in predicting the prognosis of lung adenocarcinoma.
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Abbreviation {#sec2-5}
------------

GPS: Glasgow Prognostic Score

CRP: C-reactive protein

NSCLC: non-small cell lung cancer

HR: hazard ratio
